Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
      Description

      The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

      Conditions
      NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
      Talk to us
      RECRUITING
      The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
      Description

      Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

      Conditions
      Autoimmune EncephalitisEncephalitis
      Talk to us